Bayer: UBS maintains buy rating

(CercleFinance.com) - Bayer yesterday announced the start of a Phase III clinical trial to evaluate the efficacy and safety of its new anticoagulant Asundexian.


Asundexian, a once-daily oral drug for the prevention of thrombosis, has not yet received regulatory approval.

Following this announcement, UBS has confirmed its buy rating on the stock with a target price of 96 euros.


Copyright (c) 2022 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.